Pancreatic Cancer Research

ResearcherThe University of TokyoActive in the last 2 years

Tatsunori Suzuki

ORCID-verified (high confidence, 0.95), identity_conf@1As of 7 November 2026

Matched on ORCID iD 0000-0002-2344-7732; OpenAlex author ID A5081648528. Sources: OpenAlex.

Their work

Papers
16 (first author 1, last author 0)
Trials
0
Grants
0
Labs led
0
Collaborators
84
Papers, trials and grants by year

2018: 1 paper · 2019: none · 2020: 1 paper · 2021: none · 2022: 1 paper · 2023: 3 papers · 2024: 2 papers · 2025: 5 papers · 2026: 3 papers

Papers 16

  1. Conversion surgery for unresectable pancreatic ductal adenocarcinoma with liver metastasis at initial diagnosis: a nationwide multicenter study. Co-author DOI 10.1007/s00535-026-02432-2↗
  2. Optimizing surgical indication in patients with borderline resectable pancreatic ductal adenocarcinoma to prevent futile pancreatectomy. Co-author DOI 10.1016/j.hpb.2025.12.021↗
  3. Prognostic model for pancreatic cancer based on machine learning of routine slides and transcriptomic tumor analysis. Co-author DOI 10.1038/s41416-025-03308-7↗
  4. Association between homologous recombination deficiency and time to treatment failure to platinum-based chemotherapy for pancreatic cancer by using the C-CAT d… Co-author DOI 10.1007/s00535-024-02173-0↗
  5. Factors associated with actionable gene aberrations in pancreatic cancer based on the C-CAT database. Co-author DOI 10.1007/s00535-025-02253-9↗
  6. Risk factors for pancreatic cancer in individuals with intraductal papillary mucinous neoplasms and no high-risk stigmata during up to 5 years of surveillance:… Co-author DOI 10.1136/gutjnl-2024-333259↗
  7. Blood Group Antigen Expression in Blood and Tumor in Relation to Survival Outcomes in Resected Pancreatic Cancer, Overall and by Adjuvant Chemotherapy Regimens. Co-author DOI 10.1245/s10434-025-17289-7↗
  8. Endoscopic ultrasound-guided hepaticogastrostomy and endoscopic retrograde cholangiopancreatography-guided biliary drainage for distal malignant biliary obstru… Co-author DOI 10.5946/ce.2024.031↗
  9. Satellite double-stranded RNA induces mesenchymal transition in pancreatic cancer by regulating alternative splicing. Co-author DOI 10.1016/j.jbc.2024.105742↗
  10. Caveolin-1 expression is a predictor of survival and recurrence patterns in resected pancreatic ductal adenocarcinoma. Co-author DOI 10.1016/j.pan.2024.10.001↗
  11. Post-operative mortality and recurrence patterns in pancreatic cancer according to KRAS mutation and CDKN2A, p53, and SMAD4 expression. Co-author DOI 10.1002/cjp2.323↗
  12. Early skeletal muscle mass decline is a prognostic factor in patients receiving gemcitabine plus nab-paclitaxel for unresectable pancreatic cancer: a retrospec… Co-author DOI 10.1007/s00520-023-07659-w↗
  13. Combination of serum human satellite RNA and miR-21-5p levels as a biomarker for pancreatic cancer. First author DOI 10.1016/j.isci.2023.106021↗
  14. KRAS variant allele frequency, but not mutation positivity, associates with survival of patients with pancreatic cancer. Co-author DOI 10.1111/cas.15398↗
  15. The biological role of metabolic reprogramming in pancreatic cancer. Co-author DOI 10.1002/mco2.37↗
  16. Satellite RNA Increases DNA Damage and Accelerates Tumor Formation in Mouse Models of Pancreatic Cancer. Co-author DOI 10.1158/1541-7786.mcr-18-0139↗

Closest collaborators

The 25 strongest of 84 by collab_strength@1: shared papers, trials and grants, recent and small-team work weighing most.

  1. Mitsuhiro Fujishiro · 11 shared papers, 2022–2026 · strength 2.05
  2. Yousuke Nakai · 11 shared papers, 2022–2026 · strength 1.94
  3. Tsuyoshi Hamada · 10 shared papers, 2022–2026 · strength 1.77
  4. Kazunaga Ishigaki · 7 shared papers, 2023–2026 · strength 1.38
  5. Naminatsu Takahara · 6 shared papers, 2023–2026 · strength 1.24
  6. Kiyoshi Hasegawa · 6 shared papers, 2022–2026 · strength 1.08
  7. Hiroki Oyama · 5 shared papers, 2023–2025 · strength 0.88
  8. Yosuke Inoue · 5 shared papers, 2022–2026 · strength 0.81
  9. Manabu Takamatsu · 5 shared papers, 2022–2026 · strength 0.79
  10. Tsuyoshi Takeda · 5 shared papers, 2022–2026 · strength 0.79
  11. Yu Takahashi · 5 shared papers, 2022–2026 · strength 0.79
  12. Naoki Sasahira · 5 shared papers, 2022–2026 · strength 0.79
  13. Kazuhiko Koike · 5 shared papers, 2018–2024 · strength 0.65
  14. Minoru Kitago · 4 shared papers, 2022–2026 · strength 0.63
  15. Yohei Masugi · 4 shared papers, 2022–2026 · strength 0.63
  16. Sho Uemura · 4 shared papers, 2022–2026 · strength 0.63
  17. Takahiro Kishikawa · 4 shared papers, 2018–2024 · strength 0.54
  18. Takahiro Seimiya · 4 shared papers, 2018–2024 · strength 0.54
  19. Motoyuki Otsuka · 4 shared papers, 2018–2024 · strength 0.54
  20. Aya Maekawa · 3 shared papers, 2024–2026 · strength 0.52
  21. Yusuke Kazami · 2 shared papers, 2026 · strength 0.46
  22. Takuma Iwata · 3 shared papers, 2020–2024 · strength 0.46
  23. Satoru Abe · 2 shared papers, 2025–2026 · strength 0.43
  24. Yosuke Uematsu · 2 shared papers, 2025–2026 · strength 0.38
  25. Yurie Tokito · 2 shared papers, 2025 · strength 0.38

How to reach this person

A chain of introductions through people who have published, run trials or held grants together (warm_path@1: fewest links first, then the strongest). Built from public records only; no contact details are kept.